Klinische Pharmakologie / Psychopharmakologie

 
 

 
 

 

Israeli Science: News from Rehovoth


  • MULTIPLE SCLEROSIS: FDA RECOMMENDATION FOR NEW DRUG
  • LEPTIN: POTENTIAL WEIGHT-LOSS DRUG LINKED TO ADULT DIABETES?

MULTIPLE SCLEROSIS

NEW DRUG RECEIVES RECOMMENDATION OF FDA ADMINISTRATION ADVISORY COMMITTEE

REHOVOT, Israel -- An advisory committee convened by the U.S. Food and Drug Administration recommended on September 1996, that the FDA approve the Israeli drug copolymer-1, to be marketed under the brand name COPAXONE®, for treatment of patients with relapsing-remitting multiple sclerosis.

Following the recommendation, the FDA is expected to grant approval for the marketing of the drug in the U.S. within the next few weeks. Copolymer-1 (COPAXONE®) is a protein-like molecule originally synthesized by Prof. Michael Sela, Prof. Ruth Arnon and Dr. Dvora Teitelbaum of the Weizmann Institute of Science in Rehovot, Israel. Yeda Research & Development Co., which deals with the commercialization of Weizmann Institute research, granted exclusive rights for manufacturing and for marketing copolymer-1 (COPAXONE®) throughout the world to Teva Pharmaceutical Industries Ltd., Israel.

The drug was further developed by Teva, with the participation of physicians and researchers from Israel and other countries. Clinical trials carried out in recent years have shown that copolymer-1 reduces the number of attacks in patients with the relapsing-remitting form of multiple sclerosis, and that it ameliorates the condition of people in the early stages of this disease.
Moreover, the drug produces almost no negative side effects.

Copolymer-1 was first clinically investigated at the Hadassah-Hebrew University Medical Center in Jerusalem and the Albert Einstein College of Medicine in New York, and follow-up trials were conducted at various other research centers. In a decisive double-blind trial carried out between 1991 and 1994, copolymer-1 was tried on several hundred patients in eleven U.S. hospitals. Following the success of these trials, a request for marketing approval for the drug was filed last year with the FDA, and, as noted above, a recommendation for such approval has just been granted.

Multiple sclerosis is an autoimmune disease that occurs when the body's immune system erroneously attacks the protective myelin coating around nerve fibers in the central nervous system. Once this coating is destroyed, signals sent along these nerves are slowed down, and at times stopped altogether. As a result, body movement becomes difficult, and partial or complete paralysis may set in.

Copolymer-1 (COPAXONE®) blocks this process in two ways: it prevents the immune-system "attacker" cells from recognizing the myelin coating, thus warding off their attack, and it also triggers the production of immune-system suppressor cells that inhibit the action of the destructive attackers.

Multiple sclerosis is a devastating disease affecting mainly young people approaching the prime of their lives. Approximately 1 million people suffer from it around the world, including some 300,000 patients in the US and an additional 350,000 in Europe.

Prof. Arnon holds the Paul Ehrlich Chair of Immunology and Prof. Sela, the W. Garfield Weston Chair of Immunology.



LEPTIN: POTENTIAL WEIGHT-LOSS DRUG MAY BE LINKED TO ADULT DIABETES

REHOVOT, Israel November 13, 1996 Leptin, the protein that made headlines two years ago when it was found to reduce obesity in mice,may be a cause of adult-onset diabetes in humans, according to a new Weizmann Institute of Science study.

The study, to be published in the November 15 edition of Science, found that high levels of leptin disrupt some of the activities of insulin, the hormone that controls blood sugar levels. Since obese humans unlike the genetically obese mice that received so much publicity are known to have high leptin levels in their blood, this finding may explain why overweight people have a tendency to develop adult-onset, or Type II, diabetes. It may also point the way towards developing new treatments for Type II diabetes, which is the most common form of diabetes and mostly strikes overweight people over the age of 40.
Moreover, this research suggests that if leptin is developed into a weight-loss drug in the future, it should be used with caution because it may cause the user to develop diabetes-related symptoms.

"We know that overweight people have higher levels of leptin. We also know that these people have a tendency towards adult-onset diabetes, and that no one is sure exactly what causes this type of diabetes," said research head Prof. Menachem Rubinstein, of the Molecular Genetics Department.
"We have now shown that excessive leptin leads to reduced activity by insulin. All the evidence now points to the probability that excessive leptin may be one of the causes of Type II diabetes, although it is probably not the only cause. More studies are needed to examine the link between excess leptin and diabetes, and to determine whether anything can be done about it."

Leptin, a protein produced in fat cells, raises body temperature and lowers food intake. It was first identified in 1994 by scientists who found that it was absent in genetically obese mice, and that daily leptin injections caused the animals to eat less and to lose weight. This research generated great hopes for leptin's development as a weight-reduction drug for human consumption.
However, further studies introduced a cautionary note, finding that injecting leptin works mainly on obese mice with agenetic defect that results in an absence of leptin. Genetically normal obese mice as well as obese humans actually have excess leptin levels. (So far, no humans are known to have a genetically caused absence of leptin.)

Rubinstein's study now sounds a further warning, and points to a new avenue of research that will investigate the connection between leptin and adult-onset diabetes. In this form of diabetes, insulin production is usually normal but blood sugar levels are not under proper control.
Balancing blood sugar levels Insulin keeps blood sugar levels balanced in several ways: when glucose from a meal enters the bloodstream, insulin ensures it is converted into glycogen and fat, stored for later use. Insulin also ensures that the stored fat is not released and turned back into glucose, a process known as gluconeogenesis, until it is needed. This double-valve process is a finely tuned balancing act that goes on minute by minute, ensuring that cells get a constant amount of energy and that blood sugar levels are not subject to wild fluctuations.

Working with cells derived from human liver and using a quantity of leptin similar to that present in the blood of obese individuals, Rubinstein and colleagues Dr. Batya Cohen and Dr. Daniela Novick found that while leptin does not affect insulin's first function, it does significantly suppress its ability to slow down gluconeogenesis a process which, in the body, would cause raised blood sugar levels.

How leptin affects insulin Leptin, insulin and other "messenger" proteins act by binding with specific receptors on a cell's membrane, rather like a ship docking, setting off a cascade of processes inside the cell. Leptin's main receptor is in the brain's hypothalamus region, but there are also leptin receptors in the liver, heart, lungs and many other organs, and their workings had not been studied.
Rubinstein's team focused on the leptin receptor in the liver, and found that when leptin binds to liver cells, the resulting cascade affects a key protein involved in insulin's own cascade, the insulin receptor substrate 1 (IRS-1), stopping it from becoming phosphorylated (the process in which phosphate molecules attach to the protein). This failure caused several processes to take place, the net effect of which was that a much greater amount of gluconeogenesis took place.

Prof. Rubinstein holds the Maurice and Edna Weiss Chair of Cytokines Research.



Wenn Sie Vorschlaege, Kritik, Kommentare, Fragen oder sonstwas fuer uns haben, bitte zoegern Sie nicht und teilen Sie es und ganz einfach mit. We'll be happy to hear from you.
e-Mail


1995© haGalil onLine / PharmacOn Line / IDPS - Munich - Kiryat haYovel

Books


DE-Titel
US-Titel

Jüdische Weisheit

 

Copyright: pharmacon.net / hagalil.com / 1997
Impressum

haGalil onLine